Lipomedix most advanced program is Promitil® (LPMX-1), which has completed a clinical Phase 1a study in cancer patients, and a Phase 1b study in advanced colon cancer.
Promitil was investigated in combination with Radiotherapy as a radiosensitizer in preclinical studies, and a Phase 1b study to examine the safety and efficacy of Promitil-based chemo-radiotherapy in patients with advanced cancer was completed. A Phase 1b study of Promitil delivered in combination with the FOLFOX chemotherapy is ongoing.
Further to this, Lipomedix pipeline includes two other products currently under preclinical development.
• Targeted form of Promitil® (LPMX-2) directed to folate receptors of cancer cells, for intra-vesical delivery in the treatment of superficial bladder cancer.
• A new and proprietary multidrug liposome formulation with greatly enhanced anticancer activity (LPMX-3).